Celgene
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Celgene sits in the top decile of US sponsors by registered trial count (#115 of 15,742 sponsors by registered trial count).
Celgene: 308 sponsored US clinical trials, 12 recruiting.
Celgene sponsors 308 registered US clinical trials on ClinicalTrials.gov, 12 of them currently recruiting, and 221 completed. 57 of these trials are in Phase 3-4 (later-stage) and 236 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Multiple Myeloma, with 11 trials.
Top-decile sponsor footprint
Celgene ranks in the top decile of sponsors by registered trial count (#115 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
221 of 282 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (78.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
308 total, page 7 of 7
Lenalidomide Safety/Efficacy in Myelodysplastic Syndromes (MDS) Associated With a Deletion (Del)(5q) Cytogenetic Abnormality
NCT00065156
A Research Study for Patients With Metastatic Renal Cell Carcinoma
NCT00106613
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
NCT00056160
Phase 1 Study OF CDC-501 in Patients With Solid Tumors
NCT00046735
CDC-501 Therapy in Relapsed or Refractory Multiple Myeloma
NCT00044018
Study of the Safety and Efficacy of CC-5013 Treatment For Patients With Myelodysplastic Syndrome
NCT00044382
Study to Determine the Safety and Preliminary Efficacy of CC-1088 in the Treatment of Myelodysplastic Syndromes
NCT00045786
A Safety Study of ABI-007 for In-Stent Restenosis
NCT00093223
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 161 |
| Phase 2 | 75 |
| Phase 3 | 56 |
| Phase 4 | 1 |
Therapeutic Areas
What is open in the Celgene pipeline
12 recruiting of 308 indexed (4% open); 221 completed (72%).
Phase mix: 57 late (III/IV) vs 236 early (I/II) (early-phase heavy).
Top condition: Multiple Myeloma (11 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Celgene: open-pipeline peers nationwide
Peers matched on 308 registered trials and 4% open enrollment, not the therapeutic-area sidebar.
Celgene sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 308 trials (± recruiting share)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 305 trials · 8% recruiting
- Allergan · 314 trials · 0% recruiting
- University of Arkansas · 318 trials · 12% recruiting
- Rush University Medical Center · 320 trials · 17% recruiting
Sponsors near 4% open enrollment (± trial volume)
- U.S. Army Medical Research and Development Command · 4% recruiting · 77 trials
- MedtronicNeuro · 4% recruiting · 51 trials
- Aldeyra Therapeutics · 4% recruiting · 26 trials
- DexCom · 4% recruiting · 26 trials
Related
What to do with this Celgene page
308 registered trials is a research-attention snapshot, not an endorsement of Celgene or any single study.
- 12 of Celgene's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Multiple Myeloma is the condition Celgene studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Multiple Myeloma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Celgene pipeline card: 308 registered trials from official public datasets.Report a data error.